Saturday June 2 Press Briefing: ASCO Press Releases with links to abstracts

(Webcasts at the bottom of page)

Earlier Ovarian Cancer Diagnoses and Treatment Seen After ACA Implementation

Conclusions: Under the Affordable Care Act, women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis. As stage and treatment are major determinants of survival, these gains under the ACA may have long-term impacts on women with ovarian cancer. 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

Conclusions: Insurance type and regional income are associated with MM survival. This may be related to affordability of OAM and merits further investigation.

MV Cox model. *

  HR 95% CI p
Age per year increase 1.04 1.04 - 1.05 < .0001
Male/female 1.06 .99 - 1.14 .098
White/black 1.07 .98 - 1.17 .124
Primary/secondary MM .95 .86 - 1.04 .242
CCI 0/≥3 .48 .39 - .59 < .0001
1/≥3 .7 .57 - .87 .002
2/≥3 .92 .72 - 1.16 .47
Academic institution/other 1.49 1.39 - 1.59 < .0001
Medicare/private insurance 1.09 .99 - 1.2 .073
Medicaid/private insurance 1.59 1.36 - 1.87 < .0001
Not insured/private insurance 1.62 1.32 - 1.99 < .0001
Other/private insurance .95 .66 - 1.39 .802
Median income in area of residence < $46k/≥ $46k 1.16 1.08 - 1.25 < .0001

* Stem cell transplant status not included (only 15.7% were reported to have received it).

 

Racial Disparities in Access to Timely Cancer Treatment Nearly Eliminated in States With Medicaid Expansion

Conclusions:Implementation of Medicaid expansions as part of the ACA differentially improved African American cancer pts’ receipt of timely treatment, reducing racial disparities in access to care.

Predictive margins of timely treatment (%).

  Pre-Expansion Post-Expansion Pre-Post Change
White 41.8 43.1 1.8
African American 39.1 44.3 6.9**
Adjusted disparity (African American vs whites) -4.9** 0.2 5.1**

** p < 0.05

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

 

Adding Enzalutamide to Standard First-Line Treatment Improves Survival for Men With Metastatic Hormone-Sensitive Prostate Cancer

Conclusions: ENZA significantly improved OS when added to SOC in mHSPC. The benefits appeared lower in those planned to receive early DOC. Results of analyses with updated follow-up triggered by this IA will be presented. Clinical trial information: NCT02446405

Group [N] HR (95% CI) NSAA
3yOS%
ENZA
3yOS%
All pts [1125] 0.66 (0.51-0.86), p = 0.0016 72 79
       
High volume disease [596] 0.74 (0.55-1.01) 63 71
Low volume disease [529] 0.48 (0.28-0.80) 82 89
 
No planned early DOC [622] 0.51 (0.36 to 0.73) 70 83
Planned early DOC [503] 0.91 (0.62 to 1.35) 74 73
       

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

The following articles were published on NEJM.org to coincide with a meeting of the American Society of Clinical Oncology. 

ORIGINAL ARTICLE

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

I.D. Davis and Others

 

Maintenance Therapy With PARP Inhibitor Olaparib Delays Progression of BRCA-Related Pancreatic Cancer

Conclusions: Maintenance olaparib provided a statistically significant and clinically meaningful improvement in PFS in mPC pts with a gBRCAm who had not progressed on PBC. Safety was consistent with the known profile for olaparib. POLO is the first phase III trial to validate a biomarker-driven treatment in PC. Clinical trial information: NCT02184195

PFS rates at select time points.*

Time,
mo
O
N = 92, %
P
N = 62, %
6 53.0 23.0
12 33.7 14.5
18 27.6 9.6
24 22.1 9.6

*Kaplan-Meier method

 

CLICK TO SEE FULL TEXT of PRESS RELEASE including ABSTRACT

The following articles were published on NEJM.org to coincide with a meeting of the American Society of Clinical Oncology. 

ORIGINAL ARTICLE

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

T. Golan and Others